Showing 8741-8750 of 8876 results for "".
- Botox Reaches 10-Year Milestone in Aestheticshttps://practicaldermatology.com/news/20120416-botox_reaches_10-year_milestone_in_aesthetics/2459824/Allergan, Inc. marked the 10-year anniversary of the FDA approval of Botox Cosmetic (onabotulinumtoxinA) to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.In the decade since Botox Cos
- Warning for Blood Clot Risk Added to Drospirenone OCPshttps://practicaldermatology.com/news/20120411-warning_for_blood_clot_risk_added_to_drospirenone_ocps/2459827/The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred t
- Medical Students Not Concerned About Skin Cancershttps://practicaldermatology.com/news/20120326-medical_students_not_concerned_about_skin_cancers/2459831/Medical students understand the causes of skin cancer but may be confused about SPF and sunscreen use, comments in recent focus groups suggest. (Arch Dermatol. 148(3):392-393) Surprisingly, most medical students
- La Roche-Posay Launches Mobile “Dermatologist By Your Side” Educationhttps://practicaldermatology.com/news/20120320-la_roche-posay_launches_mobile_dermatologist_by_your_side_education/2459835/When patients want advice on skin care products in the pharmacy or anywhere, they can dial **DERM from a mobile phone. An automated text response leads them to a dedicated YouTube.com site, featuring educational videos from dermatologists Kavita Mariwala, MD and Shirley Chi, MD. The program from
- Galderma Completes Phase 3 Rosacea Erythema Studyhttps://practicaldermatology.com/news/20120320-galderma_completes_of_phase_3_rosacea_erythema_study/2459839/Galderma Laboratories announced the completion of two independent Phase 3 clinical trials that evaluated the safety and efficacy of CD07805/47, a proprietary topical gel under investigation in patients with moderate to severe facial erythema of
- Kythera Initiates Phase 3 trials for Investigational Injectablehttps://practicaldermatology.com/news/20120320-kythera_initiates_phase_3_trials_for_investigational_injectable/2459841/Kythera Biopharmaceuticals has initiated two Phase 3 trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental fat. The Phase 3 trials, known as REFINE-1 and REFINE-2 (Randomized Doubl
- Phase 3 Trials launching for adalimumab for hidradenitis suppurativahttps://practicaldermatology.com/news/20120315-phase_3_trials_launching_for_adalimumab_for_hidradenitis_suppurativa/2459842/Two Phase 3 clinical trials are underway to evaluate the safety and efficacy of Abbott's Humira (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa (HS). The
- ASLMS to Honor David J. Cuccia, PhDhttps://practicaldermatology.com/news/20120314-aslms_to_honor_david_j_cuccia_phd/2459844/David J. Cuccia, Ph.D, Chief Technology Officer and CEO at Modulated Imaging, Inc. Irvine, California, will receive the 2012 Dr. Horace Furumoto Innovations Professional Development Grant at the Annual Conference of the American Society for Laser Medicine and Surgery
- Merz Clarifies Status of Xeomin, Appoints William (Bill) Humphries CEOhttps://practicaldermatology.com/news/20120314-merz_clarifies_status_of_xeomin_appoints_new_ceo/2459845/Following a hearing in US District Court yesterday, Merz, Inc. is clarifying the availability of Xeomin and has appointed William (Bill) D. Humphries as CEO of Merz Inc., effective March 15. Merz Pharmaceuticals, LLC will continue to sell Xeomin fo
- FDA's 45-day TV ad reviewhttps://practicaldermatology.com/news/20120313-fdas_45-day_tv_ad_review_shot_clock_in_guidance/2459846/TV ads for most prescription drugs must be submitted to FDA for pre-review 45 days before the manufacturer intends to air them, according to an FDA draft guidance in tomorrow's Federal Register. The guidance isn't a bolt from the blue but rather a case of the agency catching up on old business – i